The Expression And Clinical Significance Of PR In ER And HER2 Co-expressing Positive Breast Cancer

Objective:To retrospectively analyze and investigate the expression of PR in ER and HER2 co-expressing positive breast cancer and its effect on the disease-free survival of patients,and to guide the treatment of this type of patients.Method:SPSS22.0 statistical software was used to analyze and process all data.Descriptive analysis was used for all variables,such as frequency and percentage.The?~2 test was used for the analysis of count data.Kaplan-Meier method was used to calculate the survival rate and to describe the survival curve.Survival comparison Log-rank test was used to analyze the factors that may influence the recurrence and metastasis of ER and HER2 co-expressing positive breast cancer patients.Single factor and COX multivariate analysis was performed to screen out the risk factors affecting patients'DFS.Result:In 141 patients with ER and HER2 co-expressing positive breast cancer,PR positive patients accounted for 85.1%(120/141),and PR negative patients accounted for 14.9%(21/141).PR negative expression is significantly associated with the number of pregnancies(P=0.021),but no correlation with first-diagnosis age,tumor size,lymph node status,TNM stage,pathological type,hypertension,diabetes,number of births,expression of Ki-67,P53(P>0.05).After a median follow-up of 4.07 years,15 patients were relapsed.The univariate analysis of DFS in 141 patients in terms of first diagnosis age,tumor size,lymph node status,TNM stage,pathological type,hypertension,diabetes,number of pregnancy,number of births,targeted therapy,PR expression,Ki-67 expression,P53 expression,the results showed that the4-year disease-free survival rate of PR-negative group and positive group are72.4%and 91.2%respectively,and the difference is statistically significant(P=0.038);The 4-year disease-free survival rate in the lymph node negative group and positive group are 95.9%and 79.3%respectively,and the difference is statistically significant(P=0.007);The 4-year disease-free survival rate in no targeted therapy group and target therapy group are 84.5%and 96.8%respectively,and the results is statistically significant(P=0.027).Multivariate analysis showed that PR negative(HR=0.319,95.0%CI:0.11-0.94,P=0.038)and lymph node positive(HR=5.027,95.0%CI:1.42-17.86,P=0.013)are independent risk factors for 4-year disease-free survival in patients with ER and HER2 co-expressing positive breast cancer.Conclusion:1.In patients with ER and HER2 co-expressing positive breast cancer,negative expression of PR was significantly associated with?4 pregnancies,and patients with more than 4 pregnancies had more PR-negative expression.2.PR negative and lymph node positive are independent risk factors for DFS in patients with ER and HER2 co-expressing positive breast cancer,no targeted therapy is a risk factor for DFS in patients.Patients with PR-negative,lymph node-positive,and non-targeted therapy had relatively short disease-free survival and were prone to relapse after surgery.